ALPN
Alpine Immune Sciences
–
Index: NASDAQ; Sector: Healthcare; Industry: Biotechnology & Drugs;
Marketcap: 200.98M; Volume: 7.40K; AvgVol 3m: 81.63K; Beta: 1.16;
Cost estimate:
P/E: –; EPS: -1.78; EPS growth quarter/prev quarter: 16.30%;
EPS growth this year: 13.50%; EPS growth past 5 years: 12.20%;
EPS ttm: -1.78;
P/S: 73.02; P/B: 10.45; P/Cashflow: 2.43; P/FCF: 7.91;
Sales: 2.95M; Sales growth quarter/prev quarter: 16.70%; Sales growth past 5 years: ;
Profitability:
Gross Margin: ; Profit Margin: ; Operating Margin: ;
ROA – return on assets: -48.80%; ROE – return on equity: -125.50%; LT Debt/Equity: 0.61; Total Debt/Equity: 0.62;
Dividend: –; Dividend Yield (%): –;
Insider Ownership: 0.50%; Insider Transactions:0.00%;
Institutional Ownership: 29.80%; Institutional Transactions: -11.26%;
Data update: 07.10.2020.